In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genexine Inc.

www.genexine.com

Latest From Genexine Inc.

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Asia Deal Watch: Daiichi Sankyo Obtains Brazilian Rights To Mitsubishi Tanabe’s ALS Drug

Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.

Deals Business Strategies

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.

South Korea M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Genexine Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Genexine Inc.
  • Senior Management
  • Young Chul Sung , PhD, CTO
    Tae Kim, PhD, VP, Clin. Operations
    Kyudon Kim, EVP, COO
  • Contact Info
  • Genexine Inc.
    Phone: (82) 31 628 3200
    700 Daewangpangyo-ro, Korea Bio Park
    Bldg. B
    Bundang-gu, Seongnam-si,, 13488
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register